Autolus Therapeutics PLC (AUTL)

Currency in USD
0.907
-0.072(-7.35%)
Closed·
0.920+0.013(+1.40%)
·
Trading near 52-week Low
AUTL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.8960.980
52 wk Range
0.8962.580
Key Statistics
Prev. Close
0.98
Open
0.964
Day's Range
0.896-0.98
52 wk Range
0.896-2.58
Volume
3.9M
Average Volume (3m)
2.08M
1-Year Change
-26.2602%
Book Value / Share
0.10
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AUTL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.363
Upside
+822.00%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Autolus Therapeutics PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 8.363
(+822.00% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy10.00+1,002.54%-MaintainNov 11, 2026
H.C. Wainwright
Buy---New CoverageNov 02, 2026
Goldman Sachs
Buy5.40+495.37%6.10MaintainMay 15, 2026
H.C. Wainwright
Buy9.00+892.28%-MaintainApr 30, 2026
H.C. Wainwright
Buy9.00+892.28%-MaintainApr 09, 2026

Autolus Therapeutics PLC Earnings Call Summary for Q3/2026

  • Q3 2026 revenue hit $41.2M, up 95% YoY, beating $39.96M forecast; EPS loss of $0.21 missed estimates by $0.05 or 31.25%
  • Full-year 2026 revenue guidance raised to at or above $150M from prior $140M-$150M range; Q4 sales expected similar to Q2-Q3 levels
  • Gross margin improved to 57% from 55% in Q2 and negative margin a year ago; operating loss narrowed 39.3% to $43.5M
  • Cash runway extended into Q2 2028 with $248.4M in cash and securities; manufacturing efficiency doubled output with reduced staffing
  • Pipeline updates expected at ASH in December for AUCATZYL and AUTO8; BOBCAT MS data delayed until ECTRIMS October 2027 for complete dataset
Last Updated: 11/10/2026, 10:20 PM
Read Full Transcript

Earnings

Latest Release
Nov 10, 2026
EPS / Forecast
-0.21 / -0.16
Revenue / Forecast
41.24M / 39.96M
EPS Revisions
Last 90 days

AUTL Income Statement

Compare AUTL to Peers and Sector

Metrics to compare
AUTL
Peers
Sector
Relationship
P/E Ratio
−0.9x−1.2x−0.2x
PEG Ratio
0.07−0.010.00
Price/Book
8.8x1.5x2.6x
Price / LTM Sales
1.8x7.8x2.6x
Upside (Analyst Target)
-193.7%76.9%
Fair Value Upside
Unlock37.4%14.9%Unlock

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Employees
753

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
43.94M16.51%46.58M
Other Institutional Investors
208.01M78.15%220.49M
Public Companies & Retail Investors
14.21M5.34%15.06M
Total
266.16M100.00%282.13M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
MAK Capital One, LLC12.63%33,621,48735,639
BioNTech SE12.52%33,333,33335,333

People Also Watch

7.590
CAPR
+0.80%
11.820
IREN
-17.97%
88.91
ANT
-8.50%

FAQ

What Is the Autolus Therapeutics (AUTL) Stock Price Today?

The Autolus Therapeutics stock price today is 0.907 USD.

What Stock Exchange Does Autolus Therapeutics Trade On?

Autolus Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Autolus Therapeutics?

The stock symbol for Autolus Therapeutics is "AUTL."

What Is the Autolus Therapeutics Market Cap?

As of today, Autolus Therapeutics market cap is 260.910M USD.

What Is Autolus Therapeutics's Earnings Per Share (TTM)?

The Autolus Therapeutics EPS (TTM) is -0.96.

When Is the Next Autolus Therapeutics Earnings Date?

Autolus Therapeutics will release its next earnings report on Mar 10, 2027.

From a Technical Analysis Perspective, Is AUTL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Autolus Therapeutics Stock Split?

Autolus Therapeutics has split 0 times.

How Many Employees Does Autolus Therapeutics Have?

Autolus Therapeutics has 753 employees.

What is the current trading status of Autolus Therapeutics (AUTL)?

As of Nov 21, 2026, Autolus Therapeutics (AUTL) is trading at a price of 0.907 USD, with a previous close of 0.980 USD. The stock has fluctuated within a day range of 0.896 USD to 0.980 USD, while its 52-week range spans from 0.896 USD to 2.580 USD.

What Is Autolus Therapeutics (AUTL) Price Target According to Analysts?

The average 12-month price target for Autolus Therapeutics is 8.363 USD, with a high estimate of 11 USD and a low estimate of 5 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +822.00% Upside potential.

What Is the AUTL Premarket Price?

AUTL's last pre-market stock price is 0.984 USD. The pre-market share volume is 25,390.000, and the stock has decreased by 0.004, or 0.410%.

What Is the AUTL After Hours Price?

AUTL's last after hours stock price is 0.920 USD, the stock has decreased by 0.013, or 1.400%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.